News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
863,169 Results
Type
Article (87549)
Company Profile (827)
Press Release (774773)
Multimedia
Podcasts (179)
Webinars (28)
Section
Business (233105)
Career Advice (4140)
Deals (39813)
Drug Delivery (141)
Drug Development (91286)
Employer Resources (203)
FDA (18301)
Job Trends (17407)
News (397504)
Policy (39931)
Tag
Academia (3005)
Academic (2)
Accelerated approval (18)
Adcomms (35)
Allergies (130)
Alliances (56980)
ALS (147)
Alzheimer's disease (1693)
Antibody-drug conjugate (ADC) (268)
Approvals (18339)
Artificial intelligence (516)
Autoimmune disease (106)
Automation (30)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (167)
Biotechnology (485)
Bladder cancer (139)
Brain cancer (53)
Breast cancer (530)
Cancer (4189)
Cardiovascular disease (365)
Career advice (3562)
Career pathing (38)
CAR-T (259)
CDC (57)
Cell therapy (714)
Cervical cancer (33)
Clinical research (75847)
Collaboration (1456)
Company closure (4)
Compensation (967)
Complete response letters (63)
COVID-19 (2966)
CRISPR (85)
C-suite (629)
Cystic fibrosis (142)
Data (4975)
Decentralized trials (2)
Denatured (65)
Depression (114)
Diabetes (467)
Diagnostics (7114)
Digital health (38)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (247)
Drug pricing (196)
Drug shortages (36)
Duchenne muscular dystrophy (209)
Earnings (99341)
Editorial (55)
Employer branding (25)
Employer resources (172)
Events (133566)
Executive appointments (998)
FDA (20900)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (16)
Funding (1310)
Gene editing (181)
Generative AI (52)
Gene therapy (569)
GLP-1 (1043)
Government (5395)
Grass and pollen (8)
Guidances (374)
Healthcare (20939)
HIV (49)
Huntington's disease (41)
IgA nephropathy (68)
Immunology and inflammation (257)
Immuno-oncology (22)
Indications (60)
Infectious disease (3218)
Inflammatory bowel disease (192)
Inflation Reduction Act (16)
Influenza (103)
Intellectual property (201)
Interviews (816)
IPO (17932)
IRA (59)
Job creations (5197)
Job search strategy (2866)
Kidney cancer (17)
Labor market (82)
Layoffs (643)
Leadership (37)
Legal (10152)
Liver cancer (92)
Longevity (13)
Lung cancer (593)
Lymphoma (287)
Machine learning (33)
Management (66)
Manufacturing (675)
MASH (148)
Medical device (14915)
Medtech (14944)
Mergers & acquisitions (22796)
Metabolic disorders (1204)
Multiple sclerosis (141)
NASH (23)
Neurodegenerative disease (239)
Neuropsychiatric disorders (63)
Neuroscience (2772)
NextGen: Class of 2025 (7707)
Non-profit (5098)
Now hiring (60)
Obesity (582)
Opinion (316)
Ovarian cancer (143)
Pain (173)
Pancreatic cancer (179)
Parkinson's disease (246)
Partnered (32)
Patents (432)
Patient recruitment (341)
Peanut (57)
People (66373)
Pharmaceutical (145)
Pharmacy benefit managers (29)
Phase I (23395)
Phase II (32911)
Phase III (24820)
Pipeline (2957)
Policy (306)
Postmarket research (3554)
Preclinical (10574)
Press Release (72)
Prostate cancer (206)
Psychedelics (52)
Radiopharmaceuticals (283)
Rare diseases (716)
Real estate (7423)
Recruiting (79)
Regulatory (28160)
Reports (65)
Research institute (2698)
Resumes & cover letters (651)
Rett syndrome (17)
RNA editing (15)
RSV (77)
Schizophrenia (140)
Series A (215)
Series B (160)
Service/supplier (30)
Sickle cell disease (85)
Special edition (26)
Spinal muscular atrophy (170)
Sponsored (42)
Startups (4320)
State (2)
Stomach cancer (17)
Supply chain (103)
Tariffs (96)
The Weekly (112)
Vaccines (1067)
Venture capital (69)
Weight loss (412)
Women's health (62)
Worklife (21)
Date
Today (202)
Last 7 days (1116)
Last 30 days (3453)
Last 365 days (33648)
2025 (28705)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1284)
Alabama (81)
Alaska (7)
Arizona (311)
Arkansas (14)
Asia (51086)
Australia (8982)
California (9966)
Canada (2954)
China (954)
Colorado (417)
Connecticut (443)
Delaware (285)
Europe (117431)
Florida (1468)
Georgia (326)
Hawaii (3)
Idaho (67)
Illinois (830)
India (56)
Indiana (489)
Iowa (20)
Japan (339)
Kansas (127)
Kentucky (39)
Louisiana (23)
Maine (79)
Maryland (1329)
Massachusetts (7459)
Michigan (321)
Minnesota (590)
Mississippi (4)
Missouri (124)
Montana (33)
Nebraska (26)
Nevada (110)
New Hampshire (80)
New Jersey (2753)
New Mexico (32)
New York (2680)
North Carolina (1453)
North Dakota (10)
Northern California (4600)
Ohio (310)
Oklahoma (22)
Oregon (51)
Pennsylvania (2057)
Puerto Rico (20)
Rhode Island (46)
South America (1655)
South Carolina (52)
South Dakota (1)
Southern California (3797)
Tennessee (153)
Texas (1559)
United States (36581)
Utah (300)
Virginia (255)
Washington D.C. (84)
Washington State (848)
West Virginia (4)
Wisconsin (103)
Wyoming (2)
There are 863,169 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
Wegovy, Casgevy Among Latest FDA Priority Review Voucher Recipients
The FDA awards a second round of Commissioner’s National Priority vouchers to six larger biopharma companies. And this time, with the exception of Eli Lilly’s orforglipron, the vouchers are for drugs that are already on the market.
November 6, 2025
·
3 min read
·
Dan Samorodnitsky
Drug pricing
White House Strikes GLP-1 Pricing Deal With Lilly, Novo
The agreement will also secure a $150 price for future weight loss pills from Novo Nordisk and Eli Lilly—at least initially.
November 6, 2025
·
3 min read
·
Annalee Armstrong
Earnings
Moderna Posts Fourth-Straight Earnings Drop but the Bleeding Is Slowing
The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting campaign is helping to stem the downward trend.
November 6, 2025
·
2 min read
·
Dan Samorodnitsky
Obesity
Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss
The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst expectations and highlighting a “potentially best in class profile,” according to BMO Capital Markets.
November 6, 2025
·
3 min read
·
Heather McKenzie
Press Releases
Neural’s Portfolio Company Hanf.com Expands Retail Footprint to Northern Germany with Two New Stores in Bielefeld and Herford
November 6, 2025
·
5 min read
Press Releases
Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
November 6, 2025
·
4 min read
Press Releases
Gene Therapy Platform Market Size to Hit USD 9.05 Billion by 2034, Driven by Advancements in CRISPR and Personalized Medicine
November 6, 2025
·
1 min read
IN PARTNERSHIP WITH PII
Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience
In this episode presented by PII, BioSpace’s head of insights discusses how to relieve clinical trial patients of technological burden to improve compliance with guests Oliver Eden and Travis Webb.
November 6, 2025
·
1 min read
·
BioSpace Insights
Earnings
AstraZeneca Builds Obesity Pipeline On ‘Medical Aspect,’ Not Aesthetics
In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based on “the medical aspect” of weight loss, including driving down visceral fat.
November 6, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Harvard Bioscience Announces Third Quarter 2025 Financial Results
November 6, 2025
·
12 min read
1 of 86,317
Next
